BiotechTube
Home/TechImmune/James F. Young, PhD
JF

James F. Young, PhD

Executive Chairman

TechImmune

Therapeutic Areas

Infectious DiseaseLong COVID

TechImmune Pipeline

DrugIndicationPhase
Long COVID ImmunotherapyTreatment of Long COVID / Post-Acute Sequelae of SARS-CoV-2 (PASC)Pre-clinical
Acute COVID-19 Antiviral TherapyTreatment of acute COVID-19, prevention of Long COVIDPre-clinical

Leadership Team at TechImmune

JU
Jeffrey Ulmer, PhD
Chief Executive Officer and Board Member
LB
Lbachir BenMohamed, PhD
Vice President and Board Member
DG
Dan Gil, PhD
Chief Operating Officer and Board Member
GH
Gavin Herbert
Vice Chairman
CD
Chris Dedic
Chief Financial Officer
View full TechImmune profile